EGFR and lung adenocarcinoma: In this real-world cohort of predominantly older adults and poor-performance status patients with advanced EGFR-mutant lung adenocarcinoma, first-line double-dose icotinib (750 mg/day) demonstrated clinically meaningful efficacy (median PFS 14.6 months, median OS 30.9 months) and a favorable safety profile.